Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;16(4):1732-1741.
doi: 10.1364/BOE.557748.

Differential artery-vein analysis in OCTA for predicting the anti-VEGF treatment outcome of diabetic macular edema

Mansour Abtahi  1 , Albert K Dadzie  1 , Behrouz Ebrahimi  1 , Boda Huang  2 , Yi-Ting Hsieh  2 , Xincheng Yao  1   3
Affiliations

Differential artery-vein analysis in OCTA for predicting the anti-VEGF treatment outcome of diabetic macular edema

Mansour Abtahi et al. Biomed Opt Express. .

Abstract

This study evaluates the role of differential artery-vein (AV) analysis in optical coherence tomography angiography (OCTA) for treatment outcome prediction of diabetic macular edema (DME). Deep learning AV segmentation in OCTA enabled the robust extraction of quantitative AV features, including perfusion intensity density (PID), blood vessel density (BVD), vessel skeleton density (VSD), vessel area flux (VAF), blood vessel caliber (BVC), blood vessel tortuosity (BVT), and vessel perimeter index (VPI). Support vector machine (SVM) classifiers were employed to predict changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Comparative analysis revealed that differential AV analysis significantly enhanced prediction performance, with BCVA accuracy improved from 70.45% to 86.36% and CRT accuracy enhanced from 68.18% to 79.55% compared to traditional OCTA analysis. These findings underscore the potential of AV analysis as a transformative tool for advancing personalized therapeutic strategies and improving clinical decision-making in managing DME.

PubMed Disclaimer

Conflict of interest statement

No competing interest exists for any author.

Figures

Fig. 1.
Fig. 1.
Illustrating the feature extraction from an OCTA image. (A) OCTA image. (B) AVA map. (C) OCTA-AV map (D) Binarized OCTA-AV map (E) Skeletonized blood vessel map in OCTA-AV map. (F) Vessel perimeter map in OCTA-AV map.
Fig. 2.
Fig. 2.
ROC curves for BCVA improvement classification: (A) before AV analysis and (B) after AV analysis; and CRT improvement classification: (C) before AV analysis and (D) after AV analysis.
See this image and copyright information in PMC

Update of

  • doi: 10.1364/opticaopen.28250855.

References

    1. Sakata K., Funatsu H., Harino S., et al. , “Relationship of macular microcirculation and retinal thickness with visual acuity in diabetic macular edema,” Ophthalmology 114(11), 2061–2069 (2007).10.1016/j.ophtha.2007.01.003 - DOI - PubMed
    1. Shin E. S., Sorenson C. M., Sheibani N., “Diabetes and retinal vascular dysfunction,” J. Ophthalmic Vision Res. 9, 362 (2014).10.4103/2008-322X.143378 - DOI - PMC - PubMed
    1. Régnier S., Malcolm W., Allen F., et al. , “Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis,” PLoS One 9(7), e102309 (2014).10.1371/journal.pone.0102309 - DOI - PMC - PubMed
    1. Urias E. A., Urias G. A., Monickaraj F., et al. , “Novel therapeutic targets in diabetic macular edema: beyond VEGF,” Vision Res. 139, 221–227 (2017).10.1016/j.visres.2017.06.015 - DOI - PubMed
    1. Cheema A. A., Cheema H. R., “Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies,” Cureus 16, e52676 (2024).10.7759/cureus.52676 - DOI - PMC - PubMed